Jefferies Starts Minerva Neurosciences (NERV) at Buy

Jefferies initiates coverage on Minerva Neurosciences (NASDAQ: NERV) with a Buy rating and a price target of $10.00 as the IPO quiet period ends.

Analyst Thomas Wei said, "We see Minerva as an undervalued neuropsychiatric company with two drugs in Phase 2 development that each address huge market opportunities. MIN-101 already has proof-of-efficacy and strong safety data and could be the first schizophrenia drug to address negative symptoms, while MIN-117 is earlier and risky but could pay off if it shows compelling efficacy in refractory depression."

For an analyst ratings summary and ratings history on Minerva Neurosciences click here. For more ratings news on Minerva Neurosciences click here.

Shares of Minerva Neurosciences closed at $6.78 yesterday.

You May Also Be Interested In